Supernus Pharmaceuticals, Inc.
SUPN
$56.50
$0.821.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.50M | -11.83M | 15.33M | 38.50M | 19.92M |
| Total Depreciation and Amortization | 21.36M | 20.38M | 18.85M | 20.10M | 20.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.19M | 8.14M | 15.36M | 2.81M | -2.11M |
| Change in Net Operating Assets | 11.49M | 13.91M | -5.13M | -7.89M | -2.90M |
| Cash from Operations | 58.54M | 30.60M | 44.41M | 53.52M | 35.62M |
| Capital Expenditure | -455.00K | -327.00K | -213.00K | -200.00K | -64.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.15M | 37.64M | -12.43M | -76.81M | -48.53M |
| Cash from Investing | -30.61M | 37.32M | -12.64M | -77.01M | -48.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.28M | 2.04M | 6.88M | 3.46M | 1.66M |
| Repurchase of Common Stock | -46.00K | -3.34M | -987.00K | -387.00K | -1.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.30M | -20.10M | -- | -- | -- |
| Cash from Financing | 935.00K | -21.40M | 5.89M | 3.08M | 1.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.86M | 46.52M | 37.66M | -20.42M | -11.31M |